Saturday 17 October 2026
Export IMTX’s income statement to Excel — free account
Immatics N.V.
IMTX Healthcare Biotechnology
Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024. In the quarter to June 2026, revenue grew 97.7%, EPS grew 19.7% and free cash flow fell 44.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.72
0.42
−5.88%
Follow IMTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
28.14 | 30.15 | 23.53 | 11.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.79) | (26.93) | (20.74) | (18.93) | |
P/B ratio |
2.98 | 2.48 | 2.35 | 2.13 | |
Price to Tangible BV |
2.99 | 2.49 | 2.35 | 2.13 | |
EV/Sales |
22.65 | 22.13 | 16.36 | 7.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.72) | (4.56) | (4.47) | (3.23) | |
EV/FCF |
(4.64) | (4.45) | (4.30) | (3.10) | |
Quick Ratio |
4.18 | 5.53 | 8.18 | 5.43 | |
Current Ratio |
7.54 | 8.78 | 11.72 | 7.36 | |
Net Debt/EBITDA |
3.62 | 4.76 | 9.49 | 6.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.08 | 0.07 | 0.08 | 0.15 | |
Operating CF/Net income |
0.96 | 0.73 | 1.50 | 0.93 | |
Capex/Depreciation |
(0.29) | (0.27) | (0.31) | (0.38) | |
Interest Coverage |
(184.64) | (148.13) | (35.85) | (189.05) | |
Research and Development Expense of Revenue |
682.54% | 777.53% | 243.69% | 909.50% | |
Selling, General and Administrative Expense of Revenue |
152.42% | 190.67% | 67.29% | 244.32% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
54.99% | 77.64% | 13.98% | 67.19% | |
Graham Net Nets |
0.29 | 0.35 | 0.38 | 0.40 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.36%) | (20.22%) | (17.52%) | (11.97%) | |
Free Cash Flow Yield |
(17.36%) | (16.48%) | (16.15%) | (20.06%) | |
Revenue per Share |
0.08 | 0.07 | 0.19 | 0.05 | |
Operating CF per Share |
(0.51) | (0.37) | (0.51) | (0.45) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.52) | (0.37) | (0.51) | (0.46) | |
Cash per Share |
1.98 | 2.62 | 3.20 | 3.22 | |
Shareholders Equity per Share |
3.40 | 3.96 | 4.48 | 4.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.40 | 3.96 | 4.48 | 4.01 | |
Free Cash Flow |
(70.98) | (50.07) | (62.95) | (56.14) | |
Working Capital |
432.80 | 502.79 | 521.57 | 462.61 | |
Capital Expenditures |
(1.00) | (0.86) | (1.00) | (1.42) | |
Net Current Asset Value |
398.90 | 465.09 | 481.72 | 416.30 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.10 | 0.04 | 0.24 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.39 | 5.38 | 6.62 | 3.49 | |
Average Payables |
29.89 | 28.17 | 21.85 | 25.32 | |
Average Assets |
604.38 | 655.93 | 694.76 | 620.43 | |
Average Common Equity |
496.01 | 549.39 | 584.87 | 453.84 |
Columns are period end dates